Clinical observation of 10 cases of stable non-segmental vitiligo in adults treated with upadacitinib.

Abstract

Objective: To evaluate the efficacy and safety of upadacitinib in treating stable nonsegmental vitiligo in adults.

Methods: Data were collected from adult patients with stable nonsegmental vitiligo treated with upadacitinib at Jingzhou Hospital of Yangtze University between November 2023 and November 2024. Treatment efficacy was compared at 8 and 16 weeks and any adverse reactions were recorded.

Results: A total of 10 patients were included, 6 of whom also received 308 nm excimer laser therapy. A total of 200 lesions were observed, with 146 receiving additional laser therapy. After 8 weeks of treatment, 60.0% of lesions achieved at least 25% pigmentation, while 27.0% achieved more than 50% pigmentation. After 16 weeks, these rates increased to 78.0% and 52.5%, respectively. Treatment efficacy was greater at 16 weeks compared to 8 weeks (p < 0.001). Acral lesions showed lower response rates compared to lesions on the face, neck, trunk, and limbs (p < 0.05). There was no statistically significant difference in efficacy between upadacitinib monotherapy and combination therapy with phototherapy (p > 0.05). Among the 10 patients, 6 achieved over 50% improvement in total VASI score after 16 weeks, while 4 showed more than 75% improvement.

Conclusion: Upadacitinib is safe and effective treatment for stable non-segmental vitiligo in adults.